Gene products differentially expressed in cancerous cells
AssigneeChiron Corporation
InventorsElizabeth Scott, George Lamson, Altaf Kassam, Guozhong Zhang, Doreen Sakamoto, Pablo Garcia, Theresa May, Giulia Kennedy, Sanmao Kang, Christoph Reinhard, Ann Jefferson
Life of this patent
Estimating the term…
Abstract
The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
Claims31
An isolated polynucleotide comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and complements thereof.
An isolated polynucleotide comprising at least 15 contiguous nucleotides of any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and which hybridizes under stringent conditions to a polynucleotide of a sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and complements thereof.
An isolated polynucleotide comprising at least 15 contiguous nucleotides of either strand of a nucleotide sequence of an insert contained in a vector deposited as clone number XXX-YYY of ATCC Deposit Number ZZZ.
An isolated polynucleotide comprising at least 15 contiguous nucleotides of any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618, said polynucleotide obtained by amplifying a fragment of cDNA using at least one polynucleotide primer comprising at least 15 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and complements thereof.
A method for detecting a cancerous cell, said method comprising:
- detecting a level of a gene product corresponding to any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and complements thereof, and
- comparing the level of gene product to a control level of said gene product;
- wherein the presence of a cancerous cell is indicated by detection of said level and comparison to a control level of gene product
A method for inhibiting a cancerous phenotype of a cell, said method comprising:
- contacting a cancerous mammalian cell with an agent for inhibition of a gene product corresponding to any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618.
A method of treating a subject with cancer, said method comprising:
- administering to a subject a pharmaceutically effective amount of an agent,
- wherein said agent modulates the activity of a gene product corresponding to any one of SEQ ID NOS:113, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618.
A method for assessing the tumor burden of a subject, said method comprising:
- detecting a level of a gene product corresponding to any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 in a test sample from a subject,
- wherein the level of said gene product in the test sample is indicative of the tumor burden in the subject.
A method for identifying an agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:
- contacting a candidate agent with a cell;
- and
- detecting modulation of a biological activity of a gene product corresponding to any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 relative to a level of biological activity of the same gene product in the absence of the candidate agent.
An isolated polypeptide encoded by any of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618, or fragment or variant thereof.
An isolated antibody that specifically binds to a polypeptide encoding by a polynucleotide consisting of a nucleotide sequence set forth in any one of SEQ ID NOS:1, 3, 5, 7, 9, 11-13, 15, 16, 18, 20, 22, 24, 26, 27, 29 and 128-1618 and complements thereof or a polypeptide having an amino acid sequence set forth in SEQ ID NOS:
- 2, 4, 6, 8, 10, 14, 17, 19, 21, 23, 25, 28 or 1619-1675.
An isolated polypeptide comprising at least 6 contiguous amino acids of SEQ ID NOS:
- 2, 4, 6, 8, 10, 14, 17, 19, 21, 23, 25, 28 or 1619-1675.
Dependencies are inferred from the claim text.